Skip to main content
BioAdvance NewsPortfolio NewsVenatorx Pharmaceuticals

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

By July 27, 2020November 1st, 2024No Comments

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

See more here